TWA
VRTX icon

TCI Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

TCI Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,000
Closed -$945K – 2242
2020
Q4 		$945K Buy
+4,000
New +$918K 0.42% 54

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCI Wealth Advisors's VRTX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 183 shares — an estimated $57.7K sold.

TCI Wealth Advisors first reported a position in VRTX in Q3 2015 and held it in 30 quarters. The position peaked at $57.7K in Q1 2023. 1,286 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 183 Vertex Pharmaceuticals shares in Q2 2023, an estimated $57.7K.
  • TCI Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q3 2015 and held it in 30 quarters.
  • TCI Wealth Advisors's Vertex Pharmaceuticals position peaked at $57.7K in Q1 2023.
  • 1,286 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.